Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bartelds GM et al. – Switchers with anti–infliximab antibodies more often develop antibodies against adalimumab than anti–TNF naive patients. Response to adalimumab was limited in switchers without anti–infliximab antibodies, which raises the question whether a second anti–TNF therapy should be offered to RA–patients who fail on initial treatment with anti–TNF, in the absence of anti–biological antibodies.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address